IRCT2015090423887N1CompletedEarly Phase 1
Evaluation the effect of silimaryn in improvement of hepatic and platlet damage in severe preeclampsia
Trial Snapshot
- Phase
- Early Phase 1
- Status
- Completed
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20 years to 30 years (—)
- Sex
- Female
Inclusion Criteria
- •age between 20 and 30 years; BMI is to be 20 to 24;Gestational age is between 35 and 42 weeks at the time of termination of pregnancy; blood pressure before the termination of pregnancy is to be more than 90/140 mm Hg;The presence of Proteinuria in random urine samples before pregnancy termination; no history of hypertension, diabetes, kidney disease, Collagen vascular and other types of cardiovascular diseases; mother is supposed to be nulliparous; Singleton pregnancy not molar; termination of pregnancy is indicated By severe pre-eclampsia
- •Exclusion criteria:presence of preeclampsia in mother
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Phase 2
To evaluate the effectiveness of Silymarin (Livergol) on IL-6 levels and size of endometrioma lesionsIRCT20150905023897N5Vice chancellor for research Tarbiat Modares University60
Recruiting
Phase 3
Silymarin in multiple SclerosisTherapeutic effect of silymarin.IRCT20171220037977N1Esfahan University of Medical Sciences60
Not yet recruiting
Phase 2
Silymarin capsule in COVID-19COVID-19 disease.COVID-19U07.1IRCT20180103038199N10Mashhad University of Medical Sciences140
Not yet recruiting
Phase 3
Effect of silymarin in inflammatory bowel diseaseK50-K52Inflammatory Bowel Disease.Noninfective inflammatory bowel diseaseIRCT20101107005123N3Mashhad University of Medical Sciences40
Completed
Phase 2
Effect of Silymarin in prevention of contrast nephropatyephropathy.Nephropathy induced by other drugs, medicaments and biological substancesIRCT2014051117648N1Isfahan University of Medical Sciences200